8th International Symposium on Hodgkin Lymphoma

 
 
 

The 8th International Symposium on Hodgkin Lymphoma was held October 24-26 in Cologne, Germany.

 

Proton therapy: The safest RT for HL?

Jen Smith Read Article
Published: 11/22/10

Hodgkin lymphoma cells
Hodgkin lymphoma cells

Comparisons of radiotherapy (RT) techniques reveal that proton therapy significantly reduces the radiation dose delivered to nontarget tissues in Hodgkin lymphoma (HL) patients. The data indicate that proton therapy is less harmful than conventional RT, intensity-modulated radiotherapy (IMRT), and 3-dimensional conformal radiotherapy (3DCRT). Bradford Hoppe, MD, of University of Florida, discussed these findings at the 8th International Symposium on Hodgkin Lymphoma. [Read Article]

Ending the chemo debate in HL

Jen Smith Read Article
Published: 11/17/10

Hodgkin lymphoma cells
Hodgkin lymphoma cells

Italian researchers’ latest findings could help settle the debate on when to use BEACOPP instead of ABVD in Hodgkin lymphoma (HL). The investigators found that ABVD and BEACOPP are comparable in efficacy when administered to HL patients with low relative tumor burden. In patients with high tumor burden, however, BEACOPP is the more effective treatment. Massimo Federico, MD, of Università di Modena e Reggio Emilia, presented these results at the 8th International Symposium on Hodgkin Lymphoma.  [Read Article]

SGN-35 is hot topic at HL symposium

Jen Smith Read Article
Published: 11/15/10

Hodgkin lymphoma cells
Hodgkin lymphoma cells

Presentations at the 8th International Symposium on Hodgkin Lymphoma suggest the anti-CD30 agent SGN-35 is active in a variety of scenarios. One presentation showed high rates of objective response in patients with relapsed or refractory Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL). A case series suggested SGN-35 is effective in patients who relapse after previous treatment with the drug. And SGN-35 appeared doubly successful in a preclinical study, demonstrating synergy with an mTOR inhibitor and preventing tumor regrowth after treatment with ABVD. [Read Article]

Resminostat shows promise in relapsed/refractory HL

Jen Smith Read Article
Published: 11/12/10

Hodgkin lymphoma cells
Hodgkin lymphoma cells

The HDAC inhibitor resminostat demonstrates antitumor activity in patients with relapsed or refractory Hodgkin lymphoma (HL) and results in negligible side effects, according to the principal investigator of the SAPHIRE study. Jan Walewski, MD, of Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, presented results from the first stage of the phase 2 study at the 8th International Symposium on Hodgkin Lymphoma. [Read Article]

PET/CT use in HL needs overhaul

Jen Smith Read Article
Published: 11/11/10

Hodgkin’s lymphoma cells
Hodgkin’s lymphoma cells

The way we use PET/CT in Hodgkin lymphoma (HL) is out-of-date, according to two speakers at the 8th International Symposium on Hodgkin Lymphoma, which took place October 23-26 in Cologne, Germany. Bruce Cheson, MD, of Georgetown University Hospital, said the current use of PET/CT in staging needs an overhaul. And Martin Hutchings, MD, PhD, of Copenhagen University Hospital, said new research indicates that routine PET/CT is no longer appropriate during follow-up. [Read Article]

Predicting survival after transplant in HL

Jen Smith Read Article
Published: 11/10/10

Bone marrow harvest
Bone marrow harvest

New research has revealed factors that can predict survival in Hodgkin lymphoma (HL) patients who relapse after autologous transplant, and these factors are predictive regardless of which post-relapse treatment patients receive. Carmen Martinez, MD, presented this research on behalf of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT) at the 8th International Symposium on Hodgkin Lymphoma. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}